Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Alpharma Seeks To Remove Stay On Generic Neurontin Approval

This article was originally published in The Pink Sheet Daily

Executive Summary

Company would launch gabapentin capsules "at risk" if stay on approval were lifted. The stay has been imposed because of dispute with Apotex regarding first-to-file exclusivity.

You may also be interested in...



Purepac Free To Launch Neurontin Generic After Court Lifts Stay

The company is not commenting on launch plans but previously said it would "commence commercial sales" if a court stay was lifted. Purepac said it would book revenues from its own gabapentin generic upon launch, but revenues received under an agreement with Teva would not be recorded until patent litigation with Pfizer is resolved.

Purepac Free To Launch Neurontin Generic After Court Lifts Stay

The company is not commenting on launch plans but previously said it would "commence commercial sales" if a court stay was lifted. Purepac said it would book revenues from its own gabapentin generic upon launch, but revenues received under an agreement with Teva would not be recorded until patent litigation with Pfizer is resolved.

Pfizer's Lyrica: "Approvable" For Three Indications, But Not Generalized Anxiety

The company received a "non-approvable" letter for the treatment of generalized anxiety disorder. Pfizer says it is working with FDA to resolve "open issues on all indications" for the Neurontin follow-on agent.

Related Content

Topics

UsernamePublicRestriction

Register

OM007836

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel